Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable TumorsHead and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Skin and Connective Tissue Diseases, carcinoma, epithelial neoplasm, head and neck squamous cell carcinoma, melanocytic neoplasm, melanoma, neoplasm, neuroendocrine neoplasm, primitive neuroectodermal tumor, skin disorder, skin neoplasm, squamous cell carcinomaRecruitingPhase 22024-03-18NCT05280314

4 results · Page 1 of 1

Swipe the table sideways for more columns.

OrganizationsLinked trials
Almac1
IO Biotech5
Merck Sharp & Dohme LLC650
Theradex4

15 results · Page 1 of 1

Swipe the table sideways for more columns.